S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

The Lancet Oncology

Volumn 9, Issue 3, 2008, Pages 215-221

  Koizumi, Wasaburo ^a   Narahara, Hiroyuki ^b   Hara, Takuo ^c   Takagane, Akinori ^d   Akiya, Toshikazu ^e   Takagi, Masakazu ^f   Miyashita, Kosei ^g   Nishizaki, Takashi ^h   Kobayashi, Osamu ⁱ   Takiyama, Wataru ^j   Toh, Yasushi ^k   Nagaie, Takashi ^l   Takagi, Seiichi ⁱ   Yamamura, Yoshitaka ^m   Yanaoka, Kimihiko ⁿ   Orita, Hiroyuki ^o   Takeuchi, Masahiro ^p  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c KOUSEIREN TAKAOKA HOSPITAL   (Japan)

^d IWATE MEDICAL UNIVERSITY   (Japan)

^e Gunma Cancer Center   (Japan)

^f SHIZUOKA GENERAL HOSPITAL   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^h MATSUYAMA RED CROSS HOSPITAL   (Japan)

ⁱ KANAGAWA CANCER CENTER   (Japan)

^j HIROSHIMA CITY ASA HOSPITAL   (Japan)

^k NATIONAL KYUSHU CANCER CENTER   (Japan)

^l ASO IIZUKA HOSPITAL   (Japan)

^m AICHI CANCER CENTER HOSPITAL   (Japan)

ⁿ WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^o Saga Prefectural Hospital Koseikan   (Japan)

^p KITASATO UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; CISPLATIN; CREATININE; ANTINEOPLASTIC ANTIMETABOLITE; OXONIC ACID; S 1 (COMBINATION); TEGAFUR; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BODY SURFACE; CANCER MORTALITY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG ERUPTION; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPONATREMIA; JAPAN; LACRIMATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; SKIN PIGMENTATION; STOMACH CANCER; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; DRUG ADMINISTRATION; DRUG COMBINATION; MIDDLE AGED; MORTALITY; STOMACH TUMOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; OXONIC ACID; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME;

EID: 40749153540     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70035-4     Document Type: Article

References (29)

1. Muñoz N., and Franceschi S. Epidemiology of gastric cancer and perspectives for prevension. Salud Publica Mex 39 (1997) 318-330
2. Kamangar F., Dores G., and Anderson W. Patterns of cancer incidence, mortality, and prevalance across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24 (2006) 2137-2150
3. Inoue M., and Tsugane S. Epidemiology of gastric cancer in Japan. Postgrad Med J 81 (2005) 419-424
4. Murad A., Santiago F., Petroianu A., Rocha P., Rodrigues M., and Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72 (1993) 37-41
5. Glimelius B., Hoffman K., Haglund U., Nyren O., and Sjoden P. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 5 (1994) 189-190
6. Pyrhönen S., Kuitunen T., Nyandoto P., and Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71 (1995) 587-591
7. Macdonald J., Schein P., Woolley P., et al. 5-fluorouracil, doxorubicin and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 93 (1980) 533-536
8. Vanhoefer U., Rougier P., Wilke H., et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18 (2000) 2648-2657
9. Ohtsu A., Shimada Y., Shirao K., et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21 (2003) 54-59
10. Preusser P., Wilke H., Achterrath W., et al. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7 (1989) 1310-1317
11. Wilke H., Preusser P., Fink U., et al. High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer-a phase II study in elderly patients or patients with cardiac risk. Invest New Drugs 8 (1990) 65-70
12. Findlay M., Cunningham D., Norman A., et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 5 (1994) 609-616
13. Cutsem E., Moiseyenko V., Tjulandin S., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24 (2006) 4991-4997
14. Kang Y., Kang W., Shin D., et al. Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results. Proc Am Soc Clin Oncol (2006) LBA4018 (abstr).
15. Cunningham D., Starling N., Rao S., et al. Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. N Engl J Med 358 (2008) 36-46
16. Shirasaka T., Shimamato Y., Ohshimo H., et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumour selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7 (1996) 548-557
17. Sugimachi K., Maehara Y., Horikoshi N., et al. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology 57 (1999) 202-210
18. Sakata Y., Ohtsu A., Horikoshi N., Sugimachi K., Mitachi Y., and Taguchi T. Late phase II study of novel oral fluoropyrimidine aniticancer drug S-1 (1M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34 (1998) 1715-1720
19. Koizumi W., Kurihara M., Nakano S., and Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 58 (2000) 191-197
20. Koizumi W., Tanabe S., Saigenji K., et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 89 (2003) 2207-2212
21. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 2nd English edn. Gastric Cancer 1 (1998) 10-24
22. Therasse P., Arbuck S., Eisenhauer E., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
23. Boku N., Yamamoto S., Shirao K., et al. Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer. (JCOG9912). Proc Am Soc Clin Oncol (2007) LBA4513 (abstr).
24. Ajani J., Faust J., Ikeda K., et al. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 23 (2005) 6957-6965
25. Shimada T., Yamazaki H., and Guengerich F. Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica 26 (1996) 395-403
26. Ajani J., Lee F., Singh D., et al. MultiCentre phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24 (2006) 663-667
27. Sakuramoto S., Sasako M., Yamaguchi T., et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357 (2007) 1810-1820
28. Nagashima F., Ohtsu A., Yoshida S., and Ito K. Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer. Gastric Cancer 8 (2005) 6-11
29. Ilson D. Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime?. J Clin Oncol 25 (2007) 3188-3190